2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Nombre del producto No. CAS Pureza Estructura química
  • HY-16254
    Hydrocortamate hydrochloride 125-03-1 98%
    Hydrocortamate hydrochloride is a broad-spectrum immunosuppressant. Hydrocortamate hydrochloride has been identified as a potential inhibitor of T cell proliferation in ischemia-reperfusion injury (IRI), specifically targeting the ANXA1 gene. Hydrocortamate hydrochloride can be used in inflammation research.
    Hydrocortamate hydrochloride
  • HY-16256
    Amrinone lactate 75898-90-7 98%
    Amrinone lactate is a positive inotropic-vasodilator agent. Amrinone lactate is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown. Amrinone lactate is also an orally active, non-glycosidic and non-catecholamine cardiotonic agent.
    Amrinone lactate
  • HY-16259
    Indecainide hydrochloride 73681-12-6 98%
    Indecainide hydrochloride is a potent and orally active class I local anesthetic antiarrhythmic agent. Indecainide hydrochloride has Na+-channel-blocking activity.
    Indecainide hydrochloride
  • HY-16357
    Octimibate 89838-96-0 98%
    Octimibate is a non-prostaglandin platelet aggregation inhibitor and cycloprostaglandin agonist. Octimibate can be used in the study of cardiovascular diseases (atherosclerosis and thrombosis).
    Octimibate
  • HY-16461
    Solenopsin 137038-57-4 98%
    Solenopsin ((-)-Solenopsin A) is an ATP-competitive and selective Akt-1 inhibitor with an IC50 of 5-10 μM, and also acts as an RSK1 inhibitor. Solenopsin inhibits the activities of PDK1 in lipid rafts, downregulates PI3K, blocks PI3K-dependent generation of 3-phosphoinositides, and suppresses the phosphorylation of FOXO1a. Solenopsin induces Mitophagy and ROS production, reduces mitochondrial oxygen consumption, and exhibits antiproliferative and antiangiogenic activities. Solenopsin can be used in research related to hyperproliferative skin diseases and malignant diseases.
    Solenopsin
  • HY-16506
    Trimethaphan camsylate 68-91-7 98%
    Trimethaphan camsylate is an arterial blood pressure lowering agent that has been shown to reduce pulmonary venous pressure in experimental pulmonary edema.
    Trimethaphan camsylate
  • HY-16622
    GSK1842799 1005407-75-9 98%
    GSK1842799 is an orally active selective S1P1 receptor agonist prodrug. GSK1842799 is promising for research of multiple sclerosis.
    GSK1842799
  • HY-16738
    Eleclazine 1443211-72-0 98.0%
    Eleclazine (GS 6615) is a selective cardiac late sodium current inhibitor and a weak inhibitor of potassium current with IC50 of <1 μM and approximately 14.2 μM, respectively. Eleclazine shows concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in porcine model. Eleclazine can be used to research cardiac arrhythmias.
    Eleclazine
  • HY-16783
    Ribuvaptan 1245620-47-6 98%
    Ribuvaptan is a vasopressin receptor antagonist. Ribuvaptan can be used for the study of Heart failure.
    Ribuvaptan
  • HY-17680
    Myosin-IN-4 2823425-92-7
    Myosin-IN-4 (Compound 3), a pyridine-2,4-dione derivative, is a myocardial myosin inhibitor. Myosin-IN-4 has a strong inhibitory activity against cardiac myosin ATPase with an IC50 value of 0.73 μM. Myosin-IN-4 exert a negative inotropic effect by inhibiting myocardial contraction. Myosin-IN-4 can be used for the research on cardiovascular diseases related to cardiac myosin.
    Myosin-IN-4
  • HY-17681
    Myosin-IN-5 2839464-02-5 98%
    Myosin-IN-5 (example 3) is a selective cardiac myosin inhibitor with an IC50 of 1.5 μM. Myosin-IN-5 shows much less effective in inhibiting skeletal myofibril activity (IC50 of 43.4 μM). Myosin-IN-5 can be used for the study of hypertrophic cardiomyopathy (HCM) and cardiac diseases.
    Myosin-IN-5
  • HY-17682
    RPR-208707 209285-84-7
    RPR-208707 is a selective factor Xa inhibitor with a Ki of 18 nM. RPR-208707 can be used for research of thrombosis-related diseases.
    RPR-208707
  • HY-18100
    PRE-084 138847-85-5 98%
    PRE-084 is a highly selective σ1 receptor (S1R) agonist, with an IC50 of 44 nM. PRE-084 exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway.
    PRE-084
  • HY-18201
    SCH-602539 618385-42-5 98%
    SCH-602539 is a selective PAR-1 antagonist. SCH-602539 inhibits platelet aggregation in response to PAR-1-selective high-affinity thrombin receptor agonist peptide. SCH-602539 exhibits synergistic antithrombotic effects when used in combination with Cangrelor (HY-19638).
    SCH-602539
  • HY-18205
    RXPA 380 564479-79-4 98%
    RXPA 380 is a C-terminal specific angiotensin-converting enzyme (ACE) inhibitor with a Ki of 3 nM. RXPA 380 inhibits C-domain mutants of human recombinant ACE with an IC50 of 2.5 nM.
    RXPA 380
  • HY-18209
    Z-13752A 193420-09-6 98%
    Z-13752A is a mercaptopropanoyl amino acid. Z-13752A inhibits NEP and ACE, with Ki values of 1.8 and 3.2 nM, respectively. Z-13752A decreases the arterial blood pressure and increases coronary blood flow. Z-13752A can be used in the research of coronary artery occlusion.
    Z-13752A
  • HY-18940
    Cilobradine 147541-45-5 98%
    Cilobradine (Cilo) is a HCN channel blocker with heart rate reducing activity. Cilobradine blocks the slow inward current of human HCN1, HCN2, HCN3, and HCN4 channels. Cilobradine has a slightly higher efficiency in blocking endogenous If in mouse sinoatrial node cells (IC50 value is 0.62μM). Cilobradine can dose-dependently reduce the heart rate from 600 to 200 bpm with an ED50 value of 1.2 mg/kg. Cilobradine induces arrhythmias at doses greater than 5 mg/kg, which are characterized by periodic fluctuations between T waves and P waves.
    Cilobradine
  • HY-19000
    ACC-9358 90446-66-5 98%
    ACC-9358 is an orally active sodium channel blocker. ACC-9358 has antiarrhythmic activity. ACC-9358 can be used in research on cardiovascular diseases such as arrhythmias.
    ACC-9358
  • HY-19003
    Isomazole 86315-52-8 98%
    Isomazole is a new cardiotonic agent. Isomazole increases the calcium sensitivity in atrial fibers and has a direct effect on contractile proteins.
    Isomazole
  • HY-19004
    711389-S hydrochloride 94899-83-9 98%
    711389-S hydrochloride is an antiarrhythmic compound that demonstrates its antiarrhythmic activity by increasing the ventricular fibrillation threshold (VFT). 711389-S hydrochloride also has strong anti-fibrillation effects and safety, and can be used in the study of ventricular fibrillation and sudden cardiac death. 711389-S hydrochloride also inhibits the sodium current.
    711389-S hydrochloride
Cat. No. Nombre del producto / Synonyms Application Reactivity